Aptargroup, Inc. · NYSE:ATR
Aptargroup — Q4 2024 Earnings Presentation
26 slides from Aptargroup's earnings presentation, Feb 7, 2025
Slide 1: Full Year and Q4 2024 Results
Full Year and Q4 2024 Results Stephan Tanda, President & CEO and Vanessa Kanu, Executive Vice President and CFO February 7, 2025
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q4 and Full Year 2024 Financial Highlights
Q4 and Full Year 2024 Financial Highlights Full Year Highlights: +1% Q4 Reported Sales +2% • Reported and core sales grew 3%, with annual sales of $3.6 billion, driven by favorable product mix and volume growth Q4 Core Sales Growth* • Delivered 30% diluted earnings per share growth and achieved 18%
Slide 4: Consistent Track Record of Returning Capital to Shareholders
Consistent Track Record of Returning Capital to Shareholders Consecutive Years Increasing Annual • Over the last five years, we have returned nearly Dividend Paid $795M to shareholders through dividends and $120 $110 share repurchases $100 • 2025 will mark our 32nd consecutive year of paying $90 $80
Slide 5: 2024 Notable Product and Technology Innovations
2024 Notable Product and Technology Innovations Pharma Beauty Closures Bidose Nasal Fragrance Pump for Fragrance Pump Tower Closure for Unidose Nasal SipNose Nasal IDScent Paper Custom Flip- System for Refillable Packaging for Alcohol-Free Plastic Squeezeable System for neffy® Delivery System Sampli
Slide 6: Recent Recognitions
Recent Recognitions Our award-winning commitment to sustainability is a competitive advantage that drives impact for our customers CDP Forbes Newsweek Time Barron’s EcoVadis CDP ISS ESG USA Today Le Point Climate A One of the In the Top 100 One of the In the Top 100 Sustainability Rating Recognized
Slide 7: Fourth Quarter 2024 Reported Results
Fourth Quarter 2024 Reported Results Q4 Reported Sales Q4 Reported EPS Q4 Highlights (in millions $) $1,200 $1.60 $1.49 1% $1.40 • Pharma’s solid performance was driven by continued $1,000 $838 $848 60% $1.20 demand for proprietary drug delivery systems used for $800 $1.00 $0.93 allergic rhinitis, e
Slide 8: Fourth Quarter 2024 Adj. EPS and Adj. EBITDA
Fourth Quarter 2024 Adj. EPS and Adj. EBITDA Q4 Adjusted EPS Q4 Adjusted EBITDA* $1.80 (in millions $) $250 $1.60 $1.52 $1.40 27% 9% $195 $200 $179 $1.20 $1.20 $1.00 $150 $0.80 $100 $0.60 $0.40 $50 $0.20 $- $- Q4 2023 Q4 2024 Q4 2023 Q4 2024 Adjustments: 24% 13% • 2023: Restructuring Initiatives of
Slide 9: Full Year 2024 Reported Results
Full Year 2024 Reported Results FY Reported Sales FY Reported EPS Full Year Highlights (in millions $) $4,000 $6.00 $5.53 $3,487 3% $3,583 30% • Aptar achieved another strong year, delivering $3,500 $5.00 $4.25 back-to-back years of double-digit earnings per $3,000 $4.00 share growth $2,500 $2,000 $
Slide 10: Full Year 2024 Adj. EPS and Adj. EBITDA
Full Year 2024 Adj. EPS and Adj. EBITDA FY Adjusted EPS* FY Adjusted EBIDTA $6.00 $5.64 $900 (in millions $) * 18% $775 $5.00 $4.79 $800 $708 9% $700 $4.00 $600 $500 $3.00 $400 $2.00 $300 $200 $1.00 $100 $- $- FY 2023 FY 2024 FY 2023 FY 2024 Adjustments: 24% 20% • 2023: Restructuring Initiatives of
Slide 11: Return on Invested Capital
Return on Invested Capital AptarGroup, Inc. - ROIC 18% 16% 14% 2024 12.5% 2023 12% 11.0% 2021 9.8% 2022 10% 8.9% 8% 6% 4% 2% 0% 2021 2022 2023 2024 Second year of increased Return on Invested Capital (ROIC) driven by growth in earnings and the realization of returns on capital investments Return on
Slide 12: Capital Allocation
Capital Allocation Segment Capex and M&A (2021-2024) Majority of capital has been allocated to our Closures faster growing, more $192M 14% profitable Pharma business Pharma* Beauty $797M $421M 56% 30% *2022 Capex is net of $28M and 2023 Capex is net of $2M of government grants received in Pharma 12
Slide 13: Outlook
Outlook Earnings Per Share Outlook Highlights $1.60 • Anticipate 2025 to be another strong year for $1.40 Q1 2025 includes: Aptar $1.23 $1.26 $1.20 $1.11 – $1.19 (compared to prior year reported) • In the first quarter we expect to experience $1.00 • Approximately 7- negative impacts from foreign cu
Slide 14: Appendix
Aptar.4 Appendix
Slide 15: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 15
Slide 16: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 16
Slide 17: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) 17
Slide 18: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 18
Slide 19: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 19
Slide 20: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands, Except Per Share Data) 20
Slide 21: Reconciliation of Adjusted EBIT After Taxes to Net Income
Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands) 21
Slide 22: Reconciliation of Capital to Stockholders' Equity
Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands) 22
Slide 23: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 23
Slide 24: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 24
Slide 25: Supplemental Information
Supplemental Information 25
Slide 26: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 26